FDG PET-MRI for the Diagnosis of Spinal Cord Lesions

Clinical Trial ID: NCT04219969


This trial studies the best time point of using F18-FDG that gives the best image on PET-MRI in patients with spinal cord lesions of unknown cause. Diagnostic procedures, such as F18-FDG PET-MRI, may help find and diagnose spinal cord lesions.

PRIMARY OBJECTIVES: I. To identify the optimal imaging time point using fludeoxyglucose F-18 (F18-FDG) positron emission tomography (PET) that gives the best lesion conspicuity as defined by the best lesion to background (L/B) ratio when evaluating spinal cord lesions of unknown etiology. EXPLORATORY OBJECTIVES: I. To identify malignancy specific factors in F18-FDG metabolism derived from metrics such as maximum standard uptake value (SUVmax), mean standard uptake value (SUVmean), total lesion glycolysis (TLG), metabolic tumor volume (MTV) and L/B ratio. OUTLINE: Patients receive fludeoxyglucose F-18 intravenously (IV) over 1 minutes and then undergo PET-magnetic resonance imaging (MRI) over 15-60 minutes at 60, 300, and 480 minutes after fludeoxyglucose F-18 injection in the absence of unacceptable toxicity.


Inclusion Criteria: - Patients with untreated intramedullary cord lesion(s) - Ability to undergo FDG PET MR examination Exclusion Criteria: - No prior surgery or biopsy of the spinal cord - No metal implanted in area of interest - Spine radiation therapy - Known allergy to FDG or gadolinium based contrast agents - Blood glucose (> 200 mg/dl) - Pregnant women are excluded - Need for conscious sedation or anesthesia in order to tolerate study

  • Start Date


  • Last Updated


  • Sponsor

    National Cancer Institute (NCI)

  • Condition Name

    Spinal Cord Neoplasm

Learn about this trial.

Check the eligibility requirements, study details, and more.

Related Trials

Different trials target different symptoms, condition types, and patients. Learn more about other emergeing treatments being investigated now.